- Home
- KZR vs XLO Comparison
KZR vs XLO Comparison
Compare KZR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZR | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1M | 39.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KZR | XLO |
|---|---|---|
| Price | $6.47 | $8.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.00 | ★ $28.00 |
| AVG Volume (30 Days) | 25.2K | ★ 319.7K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | N/A | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.53 | $0.46 |
| 52 Week High | $7.45 | $8.09 |
Technical Indicators
Market Signals| Indicator | KZR | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 91.91 |
| Support Level | $6.06 | $0.63 |
| Resistance Level | $7.35 | N/A |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | -0.08 | 0.78 |
| Stochastic Oscillator | 13.64 | 98.56 |
Price Performance
Historical ComparisonAbout KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.